Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 265305, 9 pages
http://dx.doi.org/10.1155/2012/265305
Research Article

Paraoxonase Activity and Expression Is Modulated by Therapeutics in Experimental Rat Nonalcoholic Fatty Liver Disease

1Internal Medicine Department A, Ziv Medical Center, Safed 13100, Israel
2Faculty of Medicine, Bar-Ilan University, 13100 Safed, Israel
3Oncology Unit, Ziv Medical Center, Safed 13100, Israel
4Pathology Department, Ziv Medical Center, Safed 13100, Israel
5Biotechnology Department, Ort Braude College of Engeneering, Karmiel 21982, Israel
6The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa 31096, Israel

Received 11 November 2011; Revised 16 January 2012; Accepted 23 January 2012

Academic Editor: Manuela Neuman

Copyright © 2012 O. Hussein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. La Du, “Human serum paraoxonase/aryesterase,” in Pharmacogenetics of Drug Metabolism, W. Kalow, Ed., pp. 51–91, Pergamon Press, New York, NY, USA, 1992. View at Google Scholar
  2. B. N. La Du, “Structural and functional diversity of paraoxonases,” Nature Medicine, vol. 2, no. 11, pp. 1186–1187, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Primo-Parmo, R. C. Sorenson, J. Teiber, and B. N. La Du, “The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family,” Genomics, vol. 33, no. 3, pp. 498–507, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. G. She, H. Z. Chen, Y. Yan et al., “The human paraoxonase gene cluster as a target in the treatment of atherosclerosis,” Antioxidants & Redox Signaling, vol. 16, no. 6, pp. 597–632, 2012. View at Google Scholar
  5. H. Mochizuki, S. W. Scherer, T. Xi et al., “Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence,” Gene, vol. 213, no. 1-2, pp. 149–157, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. C. J. Ng, D. J. Wadleigh, A. Gangopadhyay et al., “Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein,” Journal of Biological Chemistry, vol. 276, no. 48, pp. 44444–44449, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. C. L. Banka, “High density lipoprotein and lipoprotein oxidation,” Current Opinion in Lipidology, vol. 7, no. 3, pp. 139–142, 1996. View at Google Scholar · View at Scopus
  8. M. I. Mackness, C. Abbott, S. Arrol, and P. N. Durrington, “The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation,” Biochemical Journal, vol. 294, no. 3, pp. 829–834, 1993. View at Google Scholar · View at Scopus
  9. G. J. Kelso, W. D. Stuart, R. J. Richter, C. E. Furlong, T. C. Jordan-Starck, and J. A. K. Harmony, “Apolipoprotein J is associated with paraoxonase in human plasma,” Biochemistry, vol. 33, no. 3, pp. 832–839, 1994. View at Google Scholar · View at Scopus
  10. I. Leviev, F. Negro, and R. W. James, “Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2935–2939, 1997. View at Google Scholar · View at Scopus
  11. R. C. Sorenson, S. L. Primo-Parmo, C. L. Kuo, S. Adkins, O. Lockridge, and B. N. La Du, “Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 16, pp. 7187–7191, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Chalasani, M. A. Deeg, and D. W. Crabb, “Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 99, no. 8, pp. 1497–1502, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. L. A. Videla, R. Rodrigo, M. Orellana et al., “Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients,” Clinical Science, vol. 106, no. 3, pp. 261–268, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. Wu, K. Karlsson, and Å. Danielsson, “Effects of vitamins E, C and catalase on bromobenzene- and hydrogen peroxide-induced intracellular oxidation and DNA single-strand breakage in Hep G2 cells,” Journal of Hepatology, vol. 26, no. 3, pp. 669–677, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Perlemuter, A. Davit-Spraul, C. Cosson et al., “Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease,” Liver International, vol. 25, no. 5, pp. 946–953, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Baskol, M. Baskol, and D. Kocer, “Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis,” Clinical Biochemistry, vol. 40, no. 11, pp. 776–780, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Z. Yesilova, H. Yaman, C. Oktenli et al., “Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease,” American Journal of Gastroenterology, vol. 100, no. 4, pp. 850–855, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. E. Altomare, G. Vendemiale, and O. Albano, “Hepatic glutathione content in patients with alcoholic and non alcoholic liver disease,” Life Sciences, vol. 43, no. 12, pp. 991–998, 1988. View at Google Scholar · View at Scopus
  19. S. D. Nguyen and D. E. Sok, “Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action,” Free Radical Research, vol. 37, no. 12, pp. 1319–1330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Kumon, Y. Nakauchi, T. Suehiro et al., “Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells,” Amyloid, vol. 9, no. 3, pp. 160–164, 2002. View at Google Scholar · View at Scopus
  21. N. Ferré, J. Camps, M. Cabré, A. Paul, and J. Joven, “Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis,” Metabolism, vol. 50, no. 9, pp. 997–1000, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Ferré, J. Camps, E. Prats et al., “Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage,” Clinical Chemistry, vol. 48, no. 2, pp. 261–268, 2002. View at Google Scholar · View at Scopus
  23. M. Baskol, G. Baskol, K. Deniz et al., “A new marker for lipid peroxidation: serum paraoxonase activity in non-alcoholic steatohepatitis,” Turkish Journal of Gastroenterology, vol. 16, no. 3, pp. 119–123, 2005. View at Google Scholar · View at Scopus
  24. O. Hussein, M. Grosovski, E. Lasri, S. Svalb, U. Ravid, and N. Assy, “Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats,” World Journal of Gastroenterology, vol. 13, no. 3, pp. 361–368, 2007. View at Google Scholar · View at Scopus
  25. N. Assy, M. Grozovski, I. Bersudsky, S. Szvalb, and O. Hussein, “Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 12, no. 27, pp. 4369–4376, 2006. View at Google Scholar · View at Scopus
  26. A. Koteish and A. M. Diehl, “Animal models of steatohepatitis,” Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 16, no. 5, pp. 679–690, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. R. S. Hundal, M. Krssak, S. Dufour et al., “Mechanism by which metformin reduces glucose production in type 2 diabetes,” Diabetes, vol. 49, no. 12, pp. 2063–2069, 2000. View at Google Scholar · View at Scopus
  28. O. Hussein, L. Minasian, Y. Itzkovich, K. Shestatski, L. Solomon, and J. Zidan, “Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin,” British Journal of Clinical Pharmacology, vol. 65, no. 5, pp. 637–645, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. A. B. Mayerson, R. S. Hundal, S. Dufour et al., “The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes,” Diabetes, vol. 51, no. 3, pp. 797–802, 2002. View at Google Scholar · View at Scopus
  30. T. Shiuchi, M. Iwai, H. S. Li et al., “Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice,” Hypertension, vol. 43, no. 5, pp. 1003–1010, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. K. Yagi, “Lipid peroxides and human diseases,” Chemistry and Physics of Lipids, vol. 45, no. 2–4, pp. 337–351, 1987. View at Google Scholar · View at Scopus
  32. C. E. Furlong, R. J. Richter, S. L. Seidel, L. G. Costa, and A. G. Motulsky, “Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase,” Analytical Biochemistry, vol. 180, no. 2, pp. 242–247, 1989. View at Google Scholar · View at Scopus
  33. K. N. Gan, A. Smolen, H. W. Eckerson, and B. N. La Du, “Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities,” Drug Metabolism and Disposition, vol. 19, no. 1, pp. 100–106, 1991. View at Google Scholar · View at Scopus
  34. M. Rosenblat, D. Draganov, C. E. Watson, C. L. Bisgaier, B. N. La Du, and M. Aviram, “Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 3, pp. 468–474, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. M. Aviram, M. Rosenblat, S. Billecke et al., “Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants,” Free Radical Biology and Medicine, vol. 26, no. 7-8, pp. 892–904, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. B. J. Van Lenten, A. C. Wagner, M. Navab, and A. M. Fogelman, “Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6,” Journal of Biological Chemistry, vol. 276, no. 3, pp. 1923–1929, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. G. Kanigur-Sultuybek, M. Guven, I. Onaran, V. Tezcan, A. Cenani, and H. Hatemi, “The effect of metformin on insulin receptors and lipid peroxidation in alloxan and streptozotocin induced diabetes,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 6, no. 3-4, pp. 271–280, 1995. View at Google Scholar · View at Scopus
  38. O. Hussein, J. Shneider, M. Rosenblat, and M. Aviram, “Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients,” Journal of Cardiovascular Pharmacology, vol. 40, no. 1, pp. 28–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Park, T. Shima, K. Yamaguchi et al., “Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease,” Journal of Gastroenterology, vol. 46, no. 1, pp. 101–107, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. L. Tao, H. R. Liu, E. Gao et al., “Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia,” Circulation, vol. 108, no. 22, pp. 2805–2811, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. S. Koutsogiannaki, N. Evangelinos, G. Koliakos, and M. Kaloyianni, “Cytotoxic mechanisms of Zn2+ and Cd2+ involve Na+/H+ exchanger (NHE) activation by ROS,” Aquatic Toxicology, vol. 78, no. 4, pp. 315–324, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. M. Shiner, B. Fuhrman, and M. Aviram, “Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPARγ and AP-1 pathway activation,” Atherosclerosis, vol. 195, no. 2, pp. 313–321, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. Z. Ackerman, M. Oron-Herman, O. Pappo et al., “Hepatic effects of rosiglitazone in rats with the metabolic syndrome,” Basic and Clinical Pharmacology and Toxicology, vol. 107, no. 2, pp. 663–668, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. J. Van Wijk, B. Coll, M. C. Cabezas et al., “Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 12, pp. 1134–1137, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. T. Reddy, D. J. Wadleigh, V. Grijalva et al., “Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 542–547, 2001. View at Google Scholar · View at Scopus
  46. M. Aviram, E. Hardak, J. Vaya et al., “Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities,” Circulation, vol. 101, no. 21, pp. 2510–2517, 2000. View at Google Scholar · View at Scopus
  47. M. Aviram, M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du, “Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase,” Journal of Clinical Investigation, vol. 101, no. 8, pp. 1581–1590, 1998. View at Google Scholar · View at Scopus
  48. S. Horke, I. Witte, P. Wilgenbus, M. Krüger, D. Strand, and U. Förstermann, “Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation,” Circulation, vol. 115, no. 15, pp. 2055–2064, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. O. Meilhac, M. Zhou, N. Santanara, and S. Parthasarathy, “Lipid peroxides induce expression of catalase in cultured vascular cells,” Journal of Lipid Research, vol. 41, no. 8, pp. 1205–1213, 2000. View at Google Scholar · View at Scopus